151 related articles for article (PubMed ID: 9000318)
1. Lack of gender differences in neuroleptic response in patients with schizophrenia.
Pinals DA; Malhotra AK; Missar CD; Pickar D; Breier A
Schizophr Res; 1996 Dec; 22(3):215-22. PubMed ID: 9000318
[TBL] [Abstract][Full Text] [Related]
2. Clinical predictors of relapse following neuroleptic withdrawal.
Buchanan RW; Kirkpatrick B; Summerfelt A; Hanlon TE; Levine J; Carpenter WT
Biol Psychiatry; 1992 Jul; 32(1):72-8. PubMed ID: 1356490
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.
Kane JM; Carson WH; Saha AR; McQuade RD; Ingenito GG; Zimbroff DL; Ali MW
J Clin Psychiatry; 2002 Sep; 63(9):763-71. PubMed ID: 12363115
[TBL] [Abstract][Full Text] [Related]
4. A double-blind study of adjunctive carbamazepine versus placebo on excited states of schizophrenic and schizoaffective disorders.
Okuma T; Yamashita I; Takahashi R; Itoh H; Otsuki S; Watanabe S; Sarai K; Hazama H; Inanaga K
Acta Psychiatr Scand; 1989 Sep; 80(3):250-9. PubMed ID: 2573234
[TBL] [Abstract][Full Text] [Related]
5. Raloxifene Plus Antipsychotics Versus Placebo Plus Antipsychotics in Severely Ill Decompensated Postmenopausal Women With Schizophrenia or Schizoaffective Disorder: A Randomized Controlled Trial.
Weiser M; Levi L; Burshtein S; Hagin M; Matei VP; Podea D; Micluția I; Tiugan A; Păcală B; Grecu IG; Noy A; Zamora D; Davis JM
J Clin Psychiatry; 2017 Jul; 78(7):e758-e765. PubMed ID: 28541645
[TBL] [Abstract][Full Text] [Related]
6. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder.
Simpson GM; Glick ID; Weiden PJ; Romano SJ; Siu CO
Am J Psychiatry; 2004 Oct; 161(10):1837-47. PubMed ID: 15465981
[TBL] [Abstract][Full Text] [Related]
7. The retinoid X receptor agonist bexarotene relieves positive symptoms of schizophrenia: a 6-week, randomized, double-blind, placebo-controlled multicenter trial.
Lerner V; Miodownik C; Gibel A; Sirota P; Bush I; Elliot H; Benatov R; Ritsner MS
J Clin Psychiatry; 2013 Dec; 74(12):1224-32. PubMed ID: 24434091
[TBL] [Abstract][Full Text] [Related]
8. Effect of Adjunctive Raloxifene Therapy on Severity of Refractory Schizophrenia in Women: A Randomized Clinical Trial.
Kulkarni J; Gavrilidis E; Gwini SM; Worsley R; Grigg J; Warren A; Gurvich C; Gilbert H; Berk M; Davis SR
JAMA Psychiatry; 2016 Sep; 73(9):947-54. PubMed ID: 27438995
[TBL] [Abstract][Full Text] [Related]
9. An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder.
Goff DC; Posever T; Herz L; Simmons J; Kletti N; Lapierre K; Wilner KD; Law CG; Ko GN
J Clin Psychopharmacol; 1998 Aug; 18(4):296-304. PubMed ID: 9690695
[TBL] [Abstract][Full Text] [Related]
10. Randomized, double-blind 6-month comparison of olanzapine and quetiapine in patients with schizophrenia or schizoaffective disorder with prominent negative symptoms and poor functioning.
Kinon BJ; Noordsy DL; Liu-Seifert H; Gulliver AH; Ascher-Svanum H; Kollack-Walker S
J Clin Psychopharmacol; 2006 Oct; 26(5):453-61. PubMed ID: 16974184
[TBL] [Abstract][Full Text] [Related]
11. Sex differences in plasma homovanillic acid levels in schizophrenia and normal controls: relation to neuroleptic resistance.
Sumiyoshi T; Hasegawa M; Jayathilake K; Meltzer HY
Biol Psychiatry; 1997 Mar; 41(5):560-6. PubMed ID: 9046988
[TBL] [Abstract][Full Text] [Related]
12. Methylphenidate challenge as a predictor of relapse in schizophrenia.
Lieberman JA; Kane JM; Gadaleta D; Brenner R; Lesser MS; Kinon B
Am J Psychiatry; 1984 May; 141(5):633-8. PubMed ID: 6143506
[TBL] [Abstract][Full Text] [Related]
13. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder.
Potkin SG; Saha AR; Kujawa MJ; Carson WH; Ali M; Stock E; Stringfellow J; Ingenito G; Marder SR
Arch Gen Psychiatry; 2003 Jul; 60(7):681-90. PubMed ID: 12860772
[TBL] [Abstract][Full Text] [Related]
14. Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study.
Lindenmayer JP; Czobor P; Volavka J; Lieberman JA; Citrome L; Sheitman B; Chakos M; McEvoy JP
J Clin Psychiatry; 2002 Oct; 63(10):931-5. PubMed ID: 12416603
[TBL] [Abstract][Full Text] [Related]
15. Neuroleptic dose reduction in older psychotic patients.
Harris MJ; Heaton RK; Schalz A; Bailey A; Patterson TL
Schizophr Res; 1997 Oct; 27(2-3):241-8. PubMed ID: 9416653
[TBL] [Abstract][Full Text] [Related]
16. The acute efficacy of aripiprazole across the symptom spectrum of schizophrenia: a pooled post hoc analysis from 5 short-term studies.
Janicak PG; Glick ID; Marder SR; Crandall DT; McQuade RD; Marcus RN; Eudicone JM; Assunção-Talbott S
J Clin Psychiatry; 2009 Jan; 70(1):25-35. PubMed ID: 19192472
[TBL] [Abstract][Full Text] [Related]
17. A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia.
Fenton WS; Dickerson F; Boronow J; Hibbeln JR; Knable M
Am J Psychiatry; 2001 Dec; 158(12):2071-4. PubMed ID: 11729030
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial.
Addington DE; Pantelis C; Dineen M; Benattia I; Romano SJ
J Clin Psychiatry; 2004 Dec; 65(12):1624-33. PubMed ID: 15641867
[TBL] [Abstract][Full Text] [Related]
19. A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia.
Meltzer HY; Bobo WV; Roy A; Jayathilake K; Chen Y; Ertugrul A; Anil Yağcioğlu AE; Small JG
J Clin Psychiatry; 2008 Feb; 69(2):274-85. PubMed ID: 18232726
[TBL] [Abstract][Full Text] [Related]
20. Time course of antipsychotic effects of neuroleptic drugs.
Keck PE; Cohen BM; Baldessarini RJ; McElroy SL
Am J Psychiatry; 1989 Oct; 146(10):1289-92. PubMed ID: 2571305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
